|1.||Ransohoff, Richard M: 3 articles (06/2015 - 08/2013)|
|2.||Kajdacsy-Balla, Andre A: 3 articles (01/2015 - 01/2012)|
|3.||Barbolina, Maria V: 3 articles (01/2015 - 01/2012)|
|4.||Ludwig, Andreas: 3 articles (02/2013 - 05/2012)|
|5.||Jung, Steffen: 3 articles (09/2009 - 04/2007)|
|6.||Kokiko-Cochran, Olga N: 2 articles (06/2015 - 01/2015)|
|7.||Xu, Guixiang: 2 articles (06/2015 - 01/2015)|
|8.||Maphis, Nicole: 2 articles (06/2015 - 01/2015)|
|9.||Lamb, Bruce T: 2 articles (06/2015 - 01/2015)|
|10.||Bhaskar, Kiran: 2 articles (06/2015 - 01/2015)|
|1.||Acute Kidney Injury (Acute Renal Failure)
06/01/2007 - "In this study, we evaluate the following in early RA patients: the expression of fractalkine receptor (CX3CR1) on CD4+/CD28- T cells, a subset involved in atherosclerotic infiltration; the correlation between this subset and validated markers of early atherosclerosis. "
01/01/2014 - "The associations between the Fractalkine receptor (CX3CR1) gene T280M (rs3732378) and V249I (rs3732379) polymorphisms and atherosclerosis (AS) risk are conflicting. "
01/01/2014 - "Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis: a meta-analysis."
01/22/2009 - "However, the mechanistic role of CX(3)CR1 in atherogenesis remains unclear. "
06/01/2006 - "Fractalkine receptor (CX3CR1) plays a key role during atherogenesis. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
04/01/2004 - "There is evidence, however, for an association between the fractalkine receptor polymorphism (CX3CR1-I249) and coronary artery disease in both human population and function studies. "
01/01/2008 - "Role of the fractalkine receptor CX3CR1 polymorphisms V249I and T280M as risk factors for early-onset coronary artery disease in patients with no classic risk factors."
02/01/2003 - "A polymorphism in the FK receptor, CX(3)CR1, has been linked to a decrease in the incidence of coronary artery disease. "
04/01/2001 - "Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease."
12/01/2005 - "In addition, it extends a prior study that demonstrated that intrathecal fractalkine-induced mechanical allodynia is blocked by a neutralizing antibody to the rat fractalkine receptor, CX3CR1. "
08/18/2004 - "Fractalkine also appears to modulate the effects of intrathecal morphine because coadministration of morphine with intrathecal neutralizing antibody against the fractalkine receptor (CX3CR1) potentiated acute morphine analgesia and attenuated the development of tolerance, hyperalgesia, and allodynia. "
11/01/2004 - "In addition, a single injection of fractalkine receptor antagonist (neutralizing antibody against rat CX3C receptor-1; CX3CR1) delayed the development of mechanical allodynia and/or thermal hyperalgesia in two neuropathic pain models: chronic constriction injury (CCI) and sciatic inflammatory neuropathy. "
09/01/2007 - "In this study, we examined the expression of the CX(3)C receptor in human renal biopsies with interstitial fibrosis and from normal kidneys by real-time polymerase chain reaction (PCR) and immunohistochemistry. "
02/01/2008 - "The results identify the fractalkine receptor CX3CR1 as susceptibility a gene for hepatic fibrosis in HCV infection. "
08/01/2006 - "Here we demonstrate by both gene inactivation and target protein blockade that a single chemokine receptor subtype, the fractalkine receptor CX3CR1, is able to reduce both inflammation and fibrosis after ischemia-reperfusion injury in the mouse, leading to partially preserved renal function after injury. "
|3.||Toll-Like Receptors (Toll-Like Receptor)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Interleukin-17 (Interleukin 27)
|1.||Highly Active Antiretroviral Therapy (HAART)